Gut microbiome predicts personalized responses to dietary fiber in prediabetes: a randomized, open-label trial
Delei Song, Guangli Feng, Yuhang Ma, Yu Shi, Chunfang Qian, Chaoxun Wang, Jixiong Xu, Yue Li, Xuejiao Wang, Nengguang Fan, Weiping Dong, Xiaofeng Li, Jian Fan, Liping Chu, Feng Gao, Shasha He, Jiao Wang, Suijun Wang, Huimin Zhou, Quanquan Gu, Hua Wang, Bo Feng, Hao Zhang, Xueli Zhang, Li Li, Enfang Fan, Yanping Wang, Meihua Wu, Yan Zhang, Aimin Huang, Jian Teng, Yin Zhu, Rui Zhai, Xiaoying Ding, Chenhong Zhang, Yongde Peng
Abstract
Gut microbiota contributes to prediabetes progression, however, whether microbiota features can guide targeted prevention and treatment for diabetes requires validation through large-scale clinical trials. Here, in a randomized, open-label trial, we randomly assigned 802 prediabetic subjects to a usual care control group (patient education and dietary recommendations, n = 393) or a dietary fiber intervention group (n = 409) for 6 months. The primary outcome was the percentage change in whole-blood HbA1c, and secondary outcomes were the changes in other glucose, insulin, lipid, liver and kidney function, and anthropometric parameters. There were no statistically significant differences in the primary and secondary outcomes between groups. In post-hoc analysis, we reclassified subjects into four clusters using a multivariate clustering model based on age, BMI, HbA1c, HOMA2-IR and HOMA2-B. These clusters differed in metabolic status, risks of diabetes and its complications, gut microbiome and serum metabolites. Notably, dietary fiber improved glycemic control in Clusters 3 and 4, but not in Clusters 1 and 2, consistent with observed gut microbiota alleviations. By using a LightGBM machine learning model, we calculated a microbiome-based clinical decision score to predict personalized fiber intervention responses and identified individuals who can get glycemic benefits. In conclusion, our study suggests that the gut microbiota response influences the effectiveness of dietary fiber intervention and provides a clinically applicable model to guide microbiome-targeted personalized medicine for prediabetes. Clinical Trial Registry: ChiCTR1900027663.